Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALD518 for NSCLC-Related Fatigue and Cachexia
NCT00866970Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Sep 2008
- Primary completion
- Aug 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of clazakizumab in cancer cachexia, fatigue, sponsored by CSL Limited. Started Sep 2008; status: completed.
02
Drugs
clazakizumab
03
Conditions
cancer cachexiafatigue
Beyond the preview
Go deeper on NCT00866970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866970.